Freedom Capital Markets has downgraded Eli Lilly and Co (LLY) to a Hold rating from Buy, effective November 9, 2025. The stock is currently priced at $988.62.
This downgrade suggests a more cautious outlook for Eli Lilly, potentially reflecting concerns over competitive pressures, market conditions, or execution risks that could impact the company's performance. Eli Lilly, headquartered in Indianapolis, Indiana, engages in the discovery, development, manufacture, and sale of pharmaceutical products, employing approximately 47,000 people.
The company boasts a market capitalization of $886.2 billion, a P/E ratio of 48.13, and an EPS of 20.45. Its upcoming earnings report is scheduled for August 4, 2026, with an estimated EPS of $7.70 and revenue of $17.9 billion.
Analyst ratings and price targets serve as professional opinions based on research and financial models. While these assessments can offer valuable insights, they are grounded in assumptions that may not always materialize. Investment decisions should consider a range of factors, including company fundamentals, competitive positioning, and industry trends. Analyst views are one of many inputs for investors to consider.
It's important to note that analyst ratings can change as new information becomes available, and different analysts may have varying opinions on the same company. The current analyst consensus for Eli Lilly stands at 9 Strong Buy, 18 Buy, 9 Hold, with no Sell or Strong Sell ratings, indicating a general preference for the stock among analysts.